1-(1-吡咯烷甲基)苯并咪唑 | 19213-18-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-(1-吡咯烷甲基)苯并咪唑
• 英文名称: 1-(1-pyrrolidinomethyl)benzimidazole
• 英文别名: 1-(Pyrrolidin-1-ylmethyl)benzimidazole
• CAS: 19213-18-4
• 化学式: C₁₂H₁₅N₃
• mdl: MFCD00763742
• 分子量: 201.271
• InChiKey: AUKUDHWDLULGGT-UHFFFAOYSA-N

物化性质

• 沸点：
  341.1±44.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  21.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1-吡咯烷甲基)苯并咪唑 在 正丁基锂 、 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 30.0h， 生成 spiro[1(R),3,3-trimethyl[2.2.1]heptyl-2(S),5'-2'(S)-phenyl-1H,3H-oxazolo[3,4-a]benzimidazole]
  参考文献：
  名称：

  Asymmetric induction using chiral 1,2,4-triazole and benzimidazole derivatives

  摘要：

  Lithiated N-substituted 1,2,4-triazoles 3 and 8 and benzimidazole 11 reacted with (1R)-fenchone to give derivatives 5c, 9 and 12 in good yields as single diastereoisomers. (S)-Lactic acid 16 reacted with o-phenylenediamine 15 to give optically pure (S)-2-(I-hydroxyethyl)benzimidazole 17 (85%). Ring closures converted the fenchone derivative 12 into novel tricyclic fused benzimidazoles 13 and 14, and converted oxazolidine derivative 17 into compound 18 in yields of 50-70% as single diastereoisomers. Lithiated derivative 18 was alkylated to give compound 19 as a single diastereoisomer in high yield. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(97)00155-9
• 作为产物：
  描述：

  四氢吡咯 、 T406石油添加剂 、 聚合甲醛 以 水 为溶剂， 反应 1.17h， 以85.9%的产率得到1-(1-吡咯烷甲基)苯并咪唑
  参考文献：
  名称：

  Anti-inflammatory agents

  摘要：

  揭示了一种新型化合物，可用于调节白细胞介素-6（IL-6）和/或血管细胞粘附分子-1（VCAM-1）的表达，并且它们在治疗和/或预防心血管和炎症性疾病以及相关疾病状态中的用途，例如动脉粥样硬化、哮喘、关节炎、癌症、多发性硬化、牛皮癣和炎症性肠病以及自身免疫疾病。此外，还揭示了包含这些新型化合物的组合物，以及它们的制备方法。

  公开号：

  US09238640B2

文献信息

• Benzazole derivatives as histamine H4 receptor ligands
  申请人：BIOPROJET

  公开号：EP2447263A1

  公开（公告）日：2012-05-02

  The present patent application concerns new ligands of the H4-receptor of formula (I), their process of preparation and their therapeutic use.

  本专利申请涉及公式（I）的H4受体的新配体，它们的制备过程以及它们的治疗用途。
• [EN] BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS<br/>[FR] UTILISATION DE DÉRIVÉS DE BENZAZOLE EN TANT QUE LIGANDS DES RÉCEPTEURS H4 DE L'HISTAMINE
  申请人：BIOPROJET SOC CIV

  公开号：WO2012041860A1

  公开（公告）日：2012-04-05

  The present patent application concerns new Iigands of the H4-receptor of formula (I), their process of preparation and their therapeutic use.

  本专利申请涉及公式（I）的H4受体的新配体，它们的制备过程以及它们的治疗用途。
• 4-Aryl quinols and analogs thereof as therapeutic agents
  申请人：——

  公开号：US20040220236A1

  公开（公告）日：2004-11-04

  The present invention pertains to compounds of the formula (I) which are, inter alia, antiprolilferative agents, anticancer agents, anitimycohacterial agents, antituberculosis agents, and/or thioredoxin/thioredoxin reductase inhibitor: wherein: Q is ═O or ═N—S(═O) 2 —R Q ; R Q is -II or optionally substituted C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl; Ar is optionally substituted C 5-20 aryl; R O is an oxy substituent; the bond marked &agr; is a single bond or a double bond; the bond marked &bgr; is a single bond or a double bond; R 3 and R 5 are each independently ring substituents; R 2 and R 6 are each independently ring substituents; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for example, in the treatment of proliferative conditions, (e.g., cancer), mycobacterial infections (e.g., tuberculosis), and/or conditions mediated by thioredoxin/thioredoxin reductase. 1

  本发明涉及化合物的公式（I），其是抗增殖剂，抗癌剂，抗结核菌剂，抗结核病剂和/或硫氧还蛋白/硫氧还蛋白还原酶抑制剂，其中：Q是═O或═N-S（═O）2-RQ; RQ是-II或可选取代的C1-7烷基，C3-20杂环基或C5-20芳基; Ar是可选取代的C5-20芳基; RO是氧代取代基; 标记为&agr;的键是单键或双键; 标记为&bgr;的键是单键或双键; R3和R5各自独立地是环取代基; R2和R6各自独立地是环取代基; 以及其药学上可接受的盐，酯，酰胺，溶剂化合物，水合物和保护形式。本发明还涉及包含这种化合物的制药组合物，以及这种化合物和组合物的使用，无论是体外还是体内，例如，用于治疗增殖性疾病（例如癌症），结核菌感染（例如结核病）和/或由硫氧还蛋白/硫氧还蛋白还原酶介导的疾病。
• 4-aryl quinols and analogs thereof as therapeutic agents
  申请人：Stevens Francis Graham Malcolm

  公开号：US20060287396A1

  公开（公告）日：2006-12-21

  The present invention pertains to compounds of the following formula, which are, inter alia, antiproliferative agents, anticancer agents, antimycobacterial agents, antituberculosis agents, and/or thioredoxin/thioredoxin reductase inhibitors: wherein: Q is ═O or ═N—S(═O) 2 —R Q ; R Q is —H or optionally substituted C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl; Ar is optionally substituted C 5-20 aryl; R O is an oxy substituent; the bond marked α is a single bond or a double bond; the bond marked β is a single bond or a double bond; R 3 and R 5 are each independently ring substituents; R 2 and R 6 are each independently ring substituents; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for example, in the treatment of proliferative conditions, (e.g., cancer), mycobacterial infections (e.g., tuberculosis), and/or conditions mediated by thioredoxin/thioredoxin reductase.

  本发明涉及以下式的化合物，它们是抗增殖剂、抗癌剂、抗分枝杆菌剂、抗结核菌剂和/或硫氧还蛋白/硫氧还蛋白还原酶抑制剂，其中：Q为═O或═N—S(═O)2—RQ；RQ为—H或可选取代的C1-7烷基、C3-20杂环基或C5-20芳基；Ar为可选取代的C5-20芳基；RO为氧代取代基；标记为α的键为单键或双键；标记为β的键为单键或双键；R3和R5各自独立地为环取代基；R2和R6各自独立地为环取代基；以及其药学上可接受的盐、酯、酰胺、溶剂化合物、水合物和保护形式。本发明还涉及包括这样的化合物的制药组合物，以及这样的化合物和组合物的使用，无论是体外还是体内，例如在治疗增殖性疾病（例如癌症）、分枝杆菌感染（例如结核病）和/或由硫氧还蛋白/硫氧还蛋白还原酶介导的疾病中。
• NOVEL ANTI-INFLAMMATORY AGENTS
  申请人：Hansen Henrik C.

  公开号：US20120040954A1

  公开（公告）日：2012-02-16

  Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

  本发明涉及一种新型化合物，该化合物可用于调节白细胞介素-6（IL-6）和/或血管细胞黏附分子-1（VCAM-1）的表达，并且可用于治疗和/或预防心血管和炎症性疾病及相关疾病状态，例如动脉粥样硬化、哮喘、关节炎、癌症、多发性硬化症、牛皮癣和炎症性肠病以及自身免疫疾病。此外，本发明还涉及包含该新型化合物的组合物，以及其制备方法。